NCT02140320

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of RV1729 for up to 28 Days

A Randomised, Double Blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treatment With Single and Repeat Doses of Inhaled RV1729 in Healthy Subjects for up to 28 Days and Subjects With Stable Asthma for 14 Days

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 49 (actual)
• Sponsor: Respivert Ltd · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

RV1729 is a new medicine being developed for the potential treatment of asthma and smoking related lung disease (also known as chronic obstructive pulmonary disease - COPD). The objective of this study is to investigate the safety, tolerability and pharmacokinetics of single doses of RV1729 and repeat doses of RV1729 for up to 28 days.

Conditions

• Asthma
• Healthy Volunteers

Interventions

Type	Name	Description
DRUG	RV1729 single dose	Safety and tolerability of single dose
DRUG	RV1729 matching placebo single dose	Safety and tolerability of single dose
DRUG	RV1729 14 day repeat dose	Safety and tolerability of repeat doses
DRUG	RV1729 matching placebo 14 day repeat dose	Safety and tolerability of repeat doses
DRUG	RV1729 28 day repeat dose	Safety and tolerability of repeat doses
DRUG	RV1729 matching placebo 28 day repeat dose	Safety and tolerability of repeat doses

Timeline

• Start date: 2014-07-01
• Primary completion: 2015-03-01
• Completion: 2015-03-01
• First posted: 2014-05-16
• Last updated: 2015-04-14

Locations

2 sites across 1 country: United Kingdom